Publications by authors named "E R Helgeson"
Introduction: When GFR is measured (mGFR) using iohexol plasma clearance, results are reported both as a "non-indexed" (mL/min) and "body-surface area (BSA) indexed" to 1.73 m2. When these two values differ, there is no consensus as to which is preferable to use to determine suitability for living kidney donation (LKD).
View Article and Find Full Text PDFBackground: Caregivers of young children may have been particularly vulnerable to mental health challenges during the COVID-19 pandemic due to its negative impacts on their housing, finances, and childcare demands. This study explored the associations between COVID-19-related experiences and symptoms of depression and anxiety among Ugandan caregivers.
Methods: This cross-sectional study included 100 Ugandan caregivers of young children aged 6-59 months with uncomplicated malaria and iron deficiency (N = 85) and without malaria or anemia (N = 15) who were enrolled in the Optimizing Iron Status in Malaria-Endemic Areas (OptiM) study.
Objective: To compare salivary flow rates between females and males, before and after radiation therapy (RT) for head and neck cancer (HNC).
Methods: Prospective observational multicenter cohort study (OraRad). Stimulated whole salivary flow was measured before RT and at 6 and 18 months after RT.
In the general population, decreases in glomerular filtration rate (GFR) are associated with subsequent development of chronic kidney disease (CKD), cardiovascular disease (CVD), and death. It is unknown if low estimated GFR (eGFR) before or early after kidney donation was also associated with these risks. One thousand six hundred ninety-nine living donors who had both predonation and early (4-10 weeks) postdonation eGFR were included.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the impact of β-blocker prescriptions on COPD patients who experienced acute myocardial infarction (AMI), following concerns from the BLOCK-COPD trial where metoprolol was linked to increased hospitalizations.
- Conducted across 18 hospitals from June 2020 to May 2022, the research involved 579 COPD patients and aimed to evaluate the risks of mortality and adverse outcomes after starting β-blockers post-hospital discharge.
- Out of the COPD patients studied, 86.7% were prescribed β-blockers, leading to an analysis of their effects on overall health, including hospital stay lengths and respiratory events, over a six-month period.